Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Seven RNAi-Related Patent Applications: Sep 27, 2007

Premium
Title: siRNA Silencing of Influenza Virus Gene Expression
 
Number: 20070218122
 
Filed: Nov. 17, 2006
 
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics
 
The invention, the patent application’s abstract states, “provides siRNA molecules that target influenza virus gene expression and methods of using such siRNA molecules to silence influenza virus gene expression. The … invention also provides nucleic acid-lipid particles that target influenza virus gene expression comprising an siRNA that silences influenza virus gene expression, a cationic lipid, and a non-cationic lipid.”
 

 
Title: microRNA Precursors
 
Number: 20070218479
 
Filed: Dec. 28, 2006
 
Lead Inventor: Yu-Ching Chang, Industrial Technology Research Institute
 
The patent application, its abstract states, claims “methods of identifying microRNA motifs or microRNA precursors for a target gene or a set of target genes,” as well as “related computer-readable media.”
 

 
Title: Methods, Libraries, and Computer Program Products for Gene Silencing with Reduced Off-Target Effects
 
Number: 20070218495
 
Filed: March 15, 2007
 
Lead Inventor: Amanda Birmingham, Dharmacon (Thermo Fisher Scientific)
 
According to the patent application’s abstract, the invention “provides methods, libraries, and computer program products for selecting siRNA that reduce off-target effects and methods for gene silencing using these siRNAs. By comparing nucleotide sequences at positions 2-7 or 2-8 of the sense and/or antisense regions of candidate siRNAs to the 3' UTR region of mRNAs, one can select siRNAs that have reduced off-target effects.”
 

 
Title: Novel siRNA-Based Approach to Target the HIF1-Alpha Factor for Gene Therapy
 
Number: 20070218551
 
Filed: Oct. 4, 2004 PCT Filed: Oct. 4, 2004
 
Lead Inventor: Chuan-Yuan Li, Duke University
 
The invention, the patent application’s abstract states, comprises “vectors that encode small interfering RNAs designed to down regulate the expression of hypoxia-inducible genes in a cell. Also provided are compositions and host cells based upon the vectors, as well as methods of using the vectors. The [invention] further provides a method of inhibiting tumor growth infecting cells in a tumor with an adenovirus vector that encodes an siRNA directed against the hypoxia-inducible factor 1-alpha gene.”
 

 
Title: Small Interfering RNA Specific to Subunits … of the Kinase Protein CK2 and Applications of the Same
 
Number: 20070219148
 
Filed: July 2, 2004 PCT Filed: July 2, 2004
 
Lead Inventor: Beatrice Schaack, Commissariat A L'energie Atomique
 
“The invention relates to small interfering RNA specific to [certain] sub-units … of the kinase protein CK2, and to the applications of the same, especially for treating cancer and viral illnesses,” the patent application’s abstract states.
 

 
Title: Inhibition of Syk Kinase Expression
 
Number: 20070219152
 
Filed: Dec. 15, 2006
 
Lead Inventor: Alan Schreiber, University of Pennsylvania (ZaBeCor)
 
The invention “relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small interfering RNA,” the patent application’s abstract states.
 

 
Title: siRNA Targeting Azurocidin 1 (Cationic Antimicrobial Protein 37)
 
Number: 20070219362
 
Filed: April 4, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed [at] azurocidin 1 (cationic antimicrobial protein 37).”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.